Publication: European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients.
dc.contributor.author | Nyssen, Olga P | |
dc.contributor.author | Bordin, Dmitry | |
dc.contributor.author | Tepes, Bojan | |
dc.contributor.author | Pérez-Aisa, Ángeles | |
dc.contributor.author | Vaira, Dino | |
dc.contributor.author | Caldas, Maria | |
dc.contributor.author | Bujanda, Luis | |
dc.contributor.author | Castro-Fernandez, Manuel | |
dc.contributor.author | Lerang, Frode | |
dc.contributor.author | Leja, Marcis | |
dc.contributor.author | Rodrigo, Luís | |
dc.contributor.author | Rokkas, Theodore | |
dc.contributor.author | Kupcinskas, Limas | |
dc.contributor.author | Pérez-Lasala, Jorge | |
dc.contributor.author | Jonaitis, Laimas | |
dc.contributor.author | Shvets, Oleg | |
dc.contributor.author | Gasbarrini, Antonio | |
dc.contributor.author | Simsek, Halis | |
dc.contributor.author | Axon, Anthony T R | |
dc.contributor.author | Buzás, György | |
dc.contributor.author | Machado, Jose Carlos | |
dc.contributor.author | Niv, Yaron | |
dc.contributor.author | Boyanova, Lyudmila | |
dc.contributor.author | Goldis, Adrian | |
dc.contributor.author | Lamy, Vincent | |
dc.contributor.author | Tonkic, Ante | |
dc.contributor.author | Przytulski, Krzysztof | |
dc.contributor.author | Beglinger, Christoph | |
dc.contributor.author | Venerito, Marino | |
dc.contributor.author | Bytzer, Peter | |
dc.contributor.author | Capelle, Lisette | |
dc.contributor.author | Milosavljević, Tomica | |
dc.contributor.author | Milivojevic, Vladimir | |
dc.contributor.author | Veijola, Lea | |
dc.contributor.author | Molina-Infante, Javier | |
dc.contributor.author | Vologzhanina, Liudmila | |
dc.contributor.author | Fadeenko, Galina | |
dc.contributor.author | Ariño, Ines | |
dc.contributor.author | Fiorini, Giulia | |
dc.contributor.author | Garre, Ana | |
dc.contributor.author | Garrido, Jesús | |
dc.contributor.author | F Pérez, Cristina | |
dc.contributor.author | Puig, Ignasi | |
dc.contributor.author | Heluwaert, Frederic | |
dc.contributor.author | Megraud, Francis | |
dc.contributor.author | O'Morain, Colm | |
dc.contributor.author | Gisbert, Javier P | |
dc.contributor.author | Hp-EuReg Investigators | |
dc.date.accessioned | 2023-02-09T09:41:21Z | |
dc.date.available | 2023-02-09T09:41:21Z | |
dc.date.issued | 2020-09-21 | |
dc.description.abstract | The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care. International multicentre prospective non-interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events and outcomes. Data monitoring was performed to ensure data quality. Time-trend and geographical analyses were performed. 30 394 patients from 27 European countries were evaluated and 21 533 (78%) first-line empirical H. pylori treatments were included for analysis. Pretreatment resistance rates were 23% to clarithromycin, 32% to metronidazole and 13% to both. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), achieving 81.5% modified intention-to-treat eradication rate. Over 90% eradication was obtained only with 10-day bismuth quadruple or 14-day concomitant treatments. Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Time-trend analysis showed a region-dependent shift in prescriptions including abandoning triple therapies, using higher acid-inhibition and longer treatments, which was associated with an overall effectiveness increase (84%-90%). Management of H. pylori infection by European gastroenterologists is heterogeneous, suboptimal and discrepant with current recommendations. Only quadruple therapies lasting at least 10 days are able to achieve over 90% eradication rates. European recommendations are being slowly and heterogeneously incorporated into routine clinical practice, which was associated with a corresponding increase in effectiveness. | |
dc.identifier.doi | 10.1136/gutjnl-2020-321372 | |
dc.identifier.essn | 1468-3288 | |
dc.identifier.pmid | 32958544 | |
dc.identifier.unpaywallURL | https://gut.bmj.com/content/gutjnl/70/1/40.full.pdf | |
dc.identifier.uri | http://hdl.handle.net/10668/16292 | |
dc.issue.number | 1 | |
dc.journal.title | Gut | |
dc.journal.titleabbreviation | Gut | |
dc.language.iso | en | |
dc.organization | Hospital Costa del Sol | |
dc.organization | Área de Gestión Sanitaria Sur de Sevilla | |
dc.organization | AGS - Sur de Sevilla | |
dc.page.number | 40-54 | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Multicenter Study | |
dc.pubmedtype | Research Support, Non-U.S. Gov't | |
dc.rights.accessRights | open access | |
dc.subject | helicobacter pylori | |
dc.subject | helicobacter pylori - treatment | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Anti-Bacterial Agents | |
dc.subject.mesh | Drug Therapy, Combination | |
dc.subject.mesh | Europe | |
dc.subject.mesh | Female | |
dc.subject.mesh | Helicobacter Infections | |
dc.subject.mesh | Helicobacter pylori | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Practice Patterns, Physicians' | |
dc.subject.mesh | Prospective Studies | |
dc.subject.mesh | Proton Pump Inhibitors | |
dc.subject.mesh | Registries | |
dc.title | European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 70 | |
dspace.entity.type | Publication |